Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash. Under the terms of the agreement, Taiho Pharmaceutical will pay Araris $400 million upfront, with the potential for additional milestone payments of up to $740 million. The acquisition is expected to be completed in the first half of 2025 and follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023.
Araris Biotech’s up to $1.14 Billion Acquisition by Taiho Pharmaceutical